Therapeutics ID Gable – Flashcards
Unlock all answers in this set
Unlock answersSTI Risk Factors |
|
Uncomplicated Gonorrhea: Clinical Presentation |
|
Complicated Gonorrhea: Clinical Presentation |
Pelvic Inflammatory Disease Disseminated gonorrhea
|
Uncomplicated Gonorrhea Treatment: w/o allergies to beta-lactam |
Ceftriaxone 125 mg IM x 1 dose OR Cefixime 400 mg PO x 1 dose + Azithromycin 1 g x 1 dose |
Uncomplicated Gonorrhea Treatment: With allergies to beta-lactam |
Azithromycin 2 g PO x 1 dose (emerging resistance)
|
Complicated Gonorrhea Treatment: Disseminated |
Ceftriaxone IV or IM until improvement begins, then Ceftriaxone PO regimen x 7 days |
Complicated Gonorrhea Treatment: Pregnancy |
Cephalosporin OR Azithromycin |
Primary Syphilis: Clinical Presentation |
Incubation 10-90 days
Site of infection External genitalia, perianal region, mouth, throat
Signs/Symptoms Chancre sore, regional lymphadenopathy |
Secondary Syphilis: Clinical Presentation |
Incubation 2-8 weeks Site of Infection Multisystem involvement Signs/Symptoms Pruritic or nonpruritic rash, mucocutaneous lesion, flu-like symptoms |
Latent Syphilis: Clinical Presentation |
Incubation 4-10 weeks (after secondary)
Site of Infection Multisystem involvement (dormant)
Signs/Symptoms Asymptomatic |
Tertiary Syphilis: Clinical Presentation |
Incubation 10-30 years
Site of Infection CNS, heart, eyes, bones, joints
Signs/Symptoms Cardiovascular syphilis, gumma lesions present, neurosyphilis |
Primary Syphilis: Treatment/Follow up |
Benzathine PCN G IM
RPR at 6 and 12 months |
Secondary Syphilis: Treatment/Follow up |
Benzathine PCN G IM
RPR at 6 and 12 months |
Early Latent Syphilis: Treatment/Follow up |
Benzathine PCN G IM
RPR at 6 and 12 months |
Late Latent Syphilis: Treatment/Follow up |
Benzathine PCN G IM weekly x 3 weeks
OR
Aqueous crystalline PCN G IV infusion x 10-14 days
RPR at 6, 12, and 24 months |
Neurosyphilis: Treatment/Follow up |
Benzathine PCN G IM weekly x 3 weeks
OR
Aqueous crystalline PCN G IV infusion x 10-14 days
CSF examination q 6 months until clear |
Jarisch-Herxheimer Reaction |
|
Primary Syphilis Treatment: PCN Allergic Patients |
Doxycycline OR Tetracycline OR Ceftriaxone |
Secondary Syphilis Treatment: PCN Allergic Patients |
Doxycycline OR Tetracycline OR Ceftriaxone |
Early Latent Syphilis Treatment: PCN Allergic Patients |
Doxycycline OR Tetracycline OR Ceftriaxone |
Late Latent or Unknown Duration Syphilis Treatment: PCN Allergic Patients |
Doxycycline OR Tetracycline OR Ceftriaxone |
Uncomplicated Chlamydia: Clinical Presentations |
|
Complicated Chlamydia: Clinical Presentations |
PID Infertility Reiter Syndrome |
Uncomplicated Chlamydia: Treatment |
Azithromycin 1 g PO x 1 dose OR Doxycycline 100 mg PO BID x 7 days
Abstain from sexual intercourse x 7 days post treatment |
Pelvic Inflammatory Disease: Risk Factors |
Young Age Use of IUD Poor socioeconomic status |
Pelvic Inflammatory Disease: Clinical Presentations |
Results from untreated chlamydia or untreated gonorrhea
|
Pelvic Inflammatory Disease: Treatment |
PO Outpatient Regimens
Ofloxacin x 14 days OR Levofloxacin x 14 days
+ Metronidazole x 14 days
OR
Ceftriaxone x 1 dose + Doxycycline x 14 days
Parenteral Inpatient Regimen
Cefoxitin IV + Doxycycline IV |
HSV Cycle |
|
Genital Herpes: Clinical Presentation |
|
Genital Herpes: Treatment of First Clinical Episode |
Palliative (not curative)
Acyclovir x 7-10 days OR Famciclovir x 7-10 days OR Valacyclovir x 7-10 days
|
Genital Herpes: Treatment of Recurrent Infections |
Chronic Suppressive Tx (> 6 episodes/year):
Acyclovir OR Famciclovir OR Valacyclovir |
Genital Herpes: Episodic Treatment |
Acyclovir 400 mg PO TID x 5 days OR Acyclovir 800 mg PO BID x 5 days OR Acyclovir 800 mg PO TID x 2 days OR Famciclovir 125 mg PO TID x 5 days OR Valacyclovir 500 mg PO BID x 5 days OR Valacyclovir 1 g PO QD x 5 days |
Genital Herpes: Resistance to 1st Line Antivirals |
Foscarnet |
Herpes Antivirals: MOA, AEs |
MOA
AE Famciclovir: N/D, HA, fever, dizziness fatigue Valacyclovir: N/V/D, HA, abdominal pain, dizziness Acyclovir: N/V/D, HA, lethargy, dizziness, rash, nephrotoxicity |
Uncomplicated Trichomoniasis: Clinical Presentation |
Females: Scant to copious, malodorous vaginal discharge Pruritis
Males: Often asymptomatic Urethral discharge (clear to mucopurulent) |
Complicated Trichomoniasis: Clinical Presentation |
|
Trichomoniasis: Treatment |
Metronidazole 2 g PO x 1 dose OR 500 mg Po BID x 7 days
OR
Tinidazole 2 g PO x 1 dose |
Metronidazole: Counseling, AE, CI |
AE
Avoid EtOH:
|
Tinidazole: Uses, AE |
AE
Avoid EtOH:
|
Human Papillomavirus 6 is associated with: |
Development of genital warts |
Human Papillomavirus 11 is associated with: |
Development of genital warts |
Human Papillomavirus 16 is associated with: |
Increased risk of cervical neoplasia |
Human Papillomavirus 18 is associated with: |
Increased risk of cervical neoplasia |
HPV: Treatments |
Cryotherapy with liquid nitrogen or surgical removal for external warts
Patient Applied Therapy: Podofilox sol'n or gel Imiquimod cream |
Gardasil: Uses |
; |
Gardasil: AE |
|
Expedited Partner Therapy |
Azithromycin OR Cefixime |
Herpes Simplex Virus (HSV) - 1 |
Oropharyngeal disease |
Herpes Simplex Virus (HSV) - 2 |
Genital disease |